Table 1 Characteristics of healthy controls and HF patients
From: Impact of heart failure on the behavior of human neonatal stem cells in vitro
Healthy control subjects (n = 12) | Heart failure patients (n = 21) | |
|---|---|---|
Demographic data and medical history | ||
Age [years] | 40 (3, 24–71) | 60 (12, 31–82) |
Sex (male/female) | 6/6 (50%/50%) | 15/6 (71%/29%) |
Smoking status | 4 (25%) | 9 (43%) |
HF duration [month] | - | 13 (4.6, 0.3-48) |
Previous surgery | - | 0 |
Previous MI | - | 13 (62%) |
Time since most recent MI [month] | - | 2.7 (1.8, 0.1-36) |
Extent of CAD | ||
One vessel | - | 0 |
Two vessels | - | 0 |
Three vessels | - | 21 (100%) |
NYHA functional class | ||
III | - | 13 (62%) |
IV | - | 8 (38%) |
Heart rate [bpm] | - | 92 (13) |
Systolic blood pressure [mmHg] | - | 118 (26, 82–167) |
Diastolic blood pressure [mmHg] | - | 76 (19, 54–104) |
Etiology | ||
Ischemic | - | 16 (76%) |
Non-ischemic | - | 5 (24%) |
Idiopathic | - | 0 |
Echocardiographic data | ||
LVEDD [mm] | - | 153 (38, 93–232) |
LVESD [mm] | - | 73 (26, 58–149) |
LVEF [%] | - | 24.7 (13.4, 15–38) |
Surgery | ||
Ventricular assist device | - | 5 (24%) |
Bypass graft | - | 12 (57%) |
Valve | - | 5 (24%) |
Non-cardiac disease | ||
Allergy | 1 (8%) | 4 (19%) |
S.p. apoplexia | 1 (8%) | 1 (5%) |
Hypertension | 3 (25%) | 17 (81%) |
Osteoporosis | 1 (8%) | 3 (14%) |
Hypothyroidism | 2 (17%) | 0 |
Diabetes type II | 1 (8%) | 11 (52%) |
Chronic obstructive pulmonary disease | 1 (8%) | 3 (14%) |
Pharmacological therapy | ||
Aspirin | 1 (8%) | 12 (57%) |
Heparin | 0 | 15 (71%) |
Coumadin | 1 (8%) | 3 (14%) |
Statins | 1 (8%) | 14 (67%) |
Loop diuretics | 2 (17%) | 15 (71%) |
β-blockers | 1 (8%) | 5 (24%) |
Digitoxin | 0 | 8 (38%) |
Metformin | 1 (8%) | 0 |
ACE Inhibitors | 1 (8%) | 17 (81%) |
Amniodarone | 0 | 6 (29%) |
Amlodipine | 1 (8%) | 0 |
Biphosphonates | 1 (8%) | 0 |
Pantoprazole | 0 | 18 (86%) |
Catecholamines | 0 | 6 (29%) |